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ABSTRACT 
Objective: The present study emphasizes the synthesis, optimization, and evaluation of ocular in-situ gel for ophthalmic drug delivery against conjunctivitis.  
Methods: Pre-formulation studies on the drug and polymers were carried out, which included the study of various physicochemical properties of the drug 
and drug-polymer compatibility studies. The 12 different formulations were further pre-optimised by Taguchi method for determining the number of 
influential factors. Furthermore, the formulation optimization was done by using ‘Box–Behnken’ design (BBD) (Design expert 10 software) for assessing the 
effect of formulation variables on product characteristics viz. viscosity, gelation temperature (GT), and mean release time (MRT). About 13 suggested runs of 
the experiment were carried out and formulations were optimised. Finally, three batches of the optimised formulation were prepared and evaluated for in 
vitro drug release, isotonicity of formulation, anti-microbial potential, ocular irritancy, and accelerated stability testing. 
Results: Pre-formulation study confirmed the purity, solubility, and compatibility of drug measured by λmax, partition coefficient, stability study, and 
Fourier-transform infrared spectroscopy (FTIR) analysis. Taguchi screening method suggested about 12 different formulations and 3 most 
prominent influential factors including viscosity, GT, and drug release. 13 different formulations designed based on ‘BBD’ method were further 
optimised by considering the most influential factors suggested by Taguchi screening. The in vitro evaluation of the optimised formulation gave 
satisfactory results in terms of drug release, and anti-microbial activity. It was found to be isotonic with no ocular irritancy. Further, the preparation 
immediately transformed from sol to gel upon administration into cul-de-sac region of the eye due to multi-dimensional approaches utilised for in-
situ gel formation namely temperature change Pluronic, ion sensitivity due to Gellan-gum, pH sensitivity because of Carbopol. 
Conclusion: The optimised in-situ gelling ocular drug formulation showed promising potency for ophthalmic drug delivery with no irritancy due to 
the multifactorial mechanism. 
Keywords: Ocular in-situ gel, Pluronic F-127, Gellan-gum, Carbopol, Taguchi screening, Box–Behnken design 




In-situ forming formulation is an advanced system of drug delivery 
in which in-situ phase transition occurs on the surface at the site of 
application. The preparations are convenient to administer and use 
over other drug delivery systems [1]. The phase transformation of 
dosage form from liquid to gel, in in-situ gelling formulations, takes 
place due to changes in physical or chemical factors, which include, 
changes in temperature, pH, solvent, ionic concentration and trigger 
one or more mechanism for transforming the liquid into gels. Since, 
the mechanisms are not dependent on any external factors which 
enhances the simplicity and reliability of formulation, encouraging 
self-administration and improved patient compliance [1]. Previously 
researchers have attempted to develop formulations to enhance the 
precorneal residence time by injecting the drug in cul-de-sac region 
of eye,. Using the polymer dependent singular approach such as pH 
dependence (cellulose acetophthalate), temperature dependent 
(polyoxyethylene polymer), in a single polymer containing 
formulation; the concentration of Pluronic required to achieve enough 
gelling property to avoid being oozed out by tears was 30% [2]. 
Carbopol possess self-acidic nature and may irritate the individual’s 
eye which leads to excessive tearing and wash out of the formulation 
[3]. The time required to form gel is significantly large in case of 
Gellan-gum, which sometimes leads to oozing out of the instilled 
formulation due to reflex tearing before it can gel. Thus, these 
formulations dependent on the singular mechanism are more 
susceptible to failure. Also, the concentration of polymer required to 
achieve desirable properties is often too high, which ultimately 
increases the total volume and cost of manufacturing of formulation 
and more importantly overexposure of delicate tissues of eyes to the 
high concentration of polymers. Thereby, limiting the scope of the 
formulation [4]. Whereas, the combined use of polymers can help to 
develop a robust formulation that may reduce the probability of 
formulation failure and reduces the quantity of polymers required to 
develop formulation [5]. Thus, to target the limitations of the traditional 
formulation including rapid exclusion, insignificant ocular bioavailability 
and eye irritation we have proposed an innovative formulation of 
Moxifloxacin hydrochloride based on multifactorial approaches. We have 
pursued the combination of numerous mechanisms to develop a new in-
situ gelling formulation having a relatively small concentration of each 
polymer. The present investigation includes the development of an 
optimised formulation based on pre-formulation studies and its 
evaluation. For this, the different sets of combined polymers in 
miscellaneous concentration was used to the developed formulation and 
optimised by design expert software (Design-Expert® 10 software) for 
utmost release of the drug, apposite viscosity at ocular site and 
optimised gelation temperature (GT). Furthermore, the ocular irritancy 
was observed in the rabbit’s eye for 14 d. 
MATERIALS AND METHODS 
Materials 
Moxifloxacin hydrochloride was obtained as a gift sample from 
INTAS pharmaceuticals, Ahmedabad, India. Pluronic F-127, 
Carbopol, Gellan-gum were obtained as a gift sample from Jubilant 
life sciences India. All other chemicals were of analytical grade. 
Microbial culture Pseudomonas aueroginosa and Staphylococcus 
aureus were obtained from microbial type culture collection (MTCC); 
MTCC catalog no. of both are 424 and 96 respectively, and Gene 
Bank, CSIR-Institute of microbial technology, India. 
Pre-formulation studies 
Melting point 
The melting point of active pharmaceutical ingredient (API) was 
determined using digital melting point apparatus. A capillary tube having 
the diameter of 1.9 mm was broken in the length of 6 cm and one end of 
the tube was sealed off. Capillary tubes were filled with the sample up to 
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the height of 0.5 cm. The sample containing capillary tube was now 
placed into the sample holder of the apparatus. Finally, the melting point 
was determined by gradually increasing the temperature, until the 
sample melted, and the melting point range was observed. 
Determination of λmax 
In distilled water and simulated tear fluid 
10 µg/ml solution of Moxifloxacin hydrochloride was prepared in 
distilled water and simulated tear fluid (STF) and scanned for λmax in 
200-400 nm range. The composition of STF was sodium chloride 
(1.34 g), sodium bicarbonate (0.4 g), calcium chloride dihydrate (16 
mg) and water up to 200 ml. 
Preparation of standard curve 
In distilled water 
10 mg of Moxifloxacin was weighed and transferred to a volumetric flask 
of 10 ml capacity and diluted with distilled water. 1 ml of this stock 
solution was further diluted to 100 ml aliquots from the resulting 
solution were pipetted and diluted to make a standard solution 
containing 1-10 µg/ml of the drug. The absorbance of these solutions 
was measured at 288 nm by using UV-visible spectrophotometer. 
Standard curve for moxifloxacin hydrochloride was developed in double 
distilled water and STF pH 7.4 using UV spectrophotometry. 
In STF 
Similarly, distilled water dilutions of drug were prepared in STF in a 
concentration range of 1-10 µg/ml. Absorbance of these solutions 
was measured at 287 nm by using UV-visible spectrophotometer 
and standard curve was prepared. 
Fourier-transform infrared spectroscopy analysis 
IR spectrum of pure drug sample was recorded using Fourier-
transform infrared spectroscopy (FTIR) alpha with ECO ZnSe ATR 
(bruker) and compared with reference spectra of the drug. Sample 
was placed on the sample platform and squeezed between the knob 
and sample platform. 
Drug-excipient compatibility study 
Prior to the formulation of Moxifloxacin hydrochloride in-situ gel, 
the drug and excipient compatibility should be determined. The 
physical mixture of drug (Moxifloxacin hydrochloride) and 
excipients (Pluronic F-127, Carbopol, Gellan-gum) in 1:1 ratio. The 
mixture was stored in airtight, light-resistant containers for the 
duration of 14 d at 37 °C. The samples were scanned by FTIR 
spectroscopy and the spectra were analysed [6]. 
Selection of dose for incorporation in in-situ gel 
0.5% of Moxifloxacin hydrochloride was incorporated into the in-situ 
gel, which was taken as standard marketed formulation of 
Moxifloxacin containing maximum strength formulation 
recommended for the disease treatment. 
Pre-optimization of in-situ gel 
The pre-optimization of in-situ gel was done by using Taguchi 
screening design. 
Screening of influential variables 
We use Taguchi design for the screening of influential factors among 
various formulation and process variables for the development of in-
situ gel [7]. The high and low level of various variables were 
screened for their influence on property of in-situ gel. The L8 array 
layout for 7 factors like rate of stirring, Pluronic F-127, Gellan-gum, 
Carbopol, pH, and stirring time, in two-level Taguchi design was 
adopted for the pre-optimization study. Twelve formulations of in-
situ gel were prepared [8]. 
In-situ hydrogel was prepared by dispersing Pluronic F-127 into 
distilled water followed by continuous stirring for 1hr. Separately 
Gellan-gum solution was prepared by dispersing powdered Gellan-
gum into distilled water at 90 °C, followed by continuous stirring 
until the mixture reaches room temperature and Carbopol solution 
was prepared by soaking the polymer in distilled water.  
The partially dissolved solutions of polymers were kept in a 
refrigerator overnight at 4 °C [9]. Loading of Moxifloxacin 
hydrochloride into in-situ gel was done by dispersing moxifloxacin into 
a specific mixture of Pluronic, Gellan-gum, and Carbopol, followed by 
continuous stirring for 5 min. Benzalkonium chloride was also added 
as a preservative, the pH of the formulation was varied using 1 M 
hydrochloric acid or 1 M sodium hydroxide. The formulation 
concentration was given in table 1. Finally, the formulations were 
sterilised using autoclaving at 121 °C at 15 psi for 30 min. The 
formulations were stored at 4 °C. The variables used in the pre-
optimization study of in-situ gel is described in table 2 below. 
 
Table 1: Formulation of in-situ hydrogel 
S. No. Ingredients  Quantity (g) 
1 Moxifloxacin hydrochloride 0.5 
2 PluronicF-127 10-20 
3 Gellan-gum 0.1-0.5 
4 Carbopol 0.1-0.5 
5 Benzalkonium chloride 0.006 
6 Distilled water Quantity sufficient for 100 g 
 
Table 2: L12 array layout as per six factor, two-level taguchi screening designs 
S. No. Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6 
Rate of stirring (rpm) Pluronic F-127 Gellan-gum Carbopol  pH Stirring time (min) 
1 100 10 0.5 0.1 8 10 
2 10 10 0.5 0.5 8 240 
3 100 10 0.5 0.5 6 10 
4 100 10 0.1 0.5 8 240 
5 100 10 0.5 0.1 6 240 
6 10 10 0.1 0.1 6 10 
7 10 20 0.1 0.5 6 240 
8 100 20 0.1 0.1 6 10 
9 10 20 0.1 0.1 8 240 
10 10 20 0.5 0.1 6 10 
11 10 20 0.1 0.5 8 10 
12 100 20 0.5 0.5 8 240 
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Evaluation of in-situ gelling preparation 
Physical appearance 
The preparation was analysed visually for physical properties such 
as appearance, colour, homogeneity, clarity, and consistency. 
Determination of pH 
10 g of the in-situ gel was taken, and the pH of the formulation was 
evaluated using digital pH meter, calibrated using standard pH 
buffer tablets of pH 4.0 and 7.0 at 25 °C [10]. 
Drug content 
Uniform distribution of active ingredients is important to achieve 
dose uniformity. The drug content of various gels was determined by 
placing the sample (2 ml) of the in-situ gel in a 100 ml volumetric 
flask and diluting the same with STF of pH 7.4. The UV absorbance of 
the resulting sample was then measured at 287 nm and using the 
standard curve percentage drug content was determined [11]. 
In vitro release study 
In vitro release studies of the prepared formulation were done with 
the help of modified dissolution apparatus. An overnight soaked 
semi-permeable membrane was tied to one end of an open-ended 
cylindrical tube having the diameter of 3.2 cm. 2 ml of the test 
sample was placed into the dissolution apparatus using STF (pH 7.4) 
as dissolution medium. Finally, the apparatus was suspended into 
the beaker containing 100 ml of dissolution medium, maintained at 
37±2 °C and 50 rpm (by magnetic stirrer). Periodically 1 ml of 
sample was withdrawn and replaced by fresh dissolution medium. 
The aliquots were analysed at 287 nm using UV spectrophotometry. 
Mean release time-80 
MRT-80 is the time required by the formulation to release 80% of its 
drug content. The MRT of the prepared formulations were evaluated 
using UV-Vis Spectrophotometer.  







In which i represents the release sample number, n represents the 
number of release sample time, tmid represents the time at the 
midpoint between i and i-1 and ∆   represents the additional 
concentration of drug release between i and i-1 [12]. 
Gelation temperature 
GT was measured by a magnetic bar method. In brief, 10 ml of the 
formulation was taken in 20 ml beaker. The formulation was stirred 
using the magnetic bar and gradually heated at the rate of 1 °C/min. 
The temperature at phase transformation of the formulation was 
noted when the movement of magnetic bar was hindered [13, 14]. 
Rheological evaluation  
The rheological study of the formulation was measured by taking the 
sample in 150 ml beaker. Viscosity of the sample was measured 
using Brookfield viscometer LV-III, using appropriate spindle. 
Optimization of in-situ gel employing Box-Behnken design 
The results obtained by preoptimization study were evaluated for 
identification of influential factors for further optimization of the 
formulation. Among various factors screened Pluronic, Carbopol and, 
Gellan-gum were identified as most influential factors (table 3). Limits 
for the influential factors were also determined by factor influencing 
study at various factor levels [9]. Box-Behnken design (BBD) was used 
for the optimization study. Using center point (0,0,0) was observed in 
quintuplicate. Table 4 summarises the experimental design matrix of 
13 experimental runs and their factor combinations. 
Formulation by design validation 
The predictability of Formulation by Design (FbD) optimization study 
was validated using several checkpoint formulations. Using numerical 
optimization six confirmatory run formulations were prepared based on 
desirability function as a check-points for validation of FbD and optimum 
formulation selection. The predicted and observed responses of the 
formulation were compared along with construction of linear correlation 
plots of the selected six formulations. Residual plot of predicted vs 
observed response was generated and linear regression was performed, 
and the amount of percent bias (i.e. prediction error) in prediction was 
analysed against observed responses. Optimised formulation of in-situ 
gel was used in further studies. 
 
Table 3: Variables used in the formulation of in-situ gel system 
S. No. Variables Levels 
I II III 
1 Pluronic F-127 10 15 20 
2 Gellan-gum 0.1 0.3 0.5 
3 Carbopol 0.1 0.3 0.5 
 
Table 4: Combination of factors according to 3-factor box-behnken design 
Run Factors 
Pluronic F-127 Gellan-gum Carbopol 
1 10 0.3 0.5 
2 15 0.1 0.5 
3 20 0.5 0.3 
4 10 0.3 0.1 
5 15 0.1 0.1 
6 10 0.1 0.3 
7 15 0.5 0.5 
8 10 0.5 0.3 
9 20 0.3 0.1 
10 20 0.3 0.5 
11 20 0.1 0.3 
12 15 0.3 0.3 
13 15 0.5 0.1 
 
Evaluation of systematically optimised formulations 
Physical appearance 
The prepared formulations were inspected visually for their 
appearance, colour, homogeneity, clarity and consistency.  
Drug content 
Uniform distribution of active ingredients is important to achieve 
dose uniformity. The drug content of various gels was determined by 
placing the sample (2 ml) of the in-situ gel in a 100 ml volumetric 
flask and diluting the same with STF of pH 7.4. The UV absorbance of 
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the resulting sample was then measured and using the standard 
curve percentage drug content was determined. 
Antimicrobial activity  
Antimicrobial activity was performed to evaluate the efficiency of 
the optimised formulation as compared to the marketed 
formulation. For this Kirby-Bauer disk diffusion method was used 
where the drug-loaded disk of 10 mm diameter was incubated in 
nutrient agar media [15]. Nutrient media were pre-poured into the 
sterile petri plates and allowed to cool under laminar air flow. 
Microbial culture of Pseudomonas aueroginosa and Staphylococcus 
aureus were inoculated with the help of sterile cotton swabs and 
drug-loaded disks were placed in the inoculated media. After 
allowing an initial diffusion period of 2 hr, the Petri plates were 
incubated at 37±0.5 °C for 24 hr. Zone of inhibition (ZOI) was 
measured with the help of Vernier calliper. 
Sterility testing 
Sterility testing is an important parameter for ophthalmic 
preparations. We used direct inoculation method for evaluation of 
sterility of in-situ gel. 2 ml of preparation was taken using a sterile 
pipette and transferred into Thioglycolate medium and separately in 
Soybean-casein digest medium. The sample was incubated for 
minimum of 14 d at 30-35 °C and 20-25 °C respectively. 
Accelerated stability testing 
Optimised formulation of Moxifloxacin hydrochloride was tested for 
accelerated stability study (according to ICH guidelines). In brief, the 
optimised formulation was placed in glass vial closed by the grey 
butyl rubber closure and sealed with aluminum closure was stored 
in a stability study chamber at 40±2°C, 75±5% RH in both horizontal 
and vertical position for 6 mo. Periodically samples were withdrawn 
and evaluated for change in visual appearance, pH, gelling capacity, 
drug content and in vitro drug release. 
Isotonicity evaluation 
Isotonicity is an important characteristic of ophthalmic preparations. 
The preparation was mixed with a few drops of blood and was 
observed under the microscope. The integrity and shape of red blood 
cells were compared against 0.9% Sodium Chloride isotonic solution. 
Ocular irritancy 
Ocular irritancy test was done on 3 rabbit’s eyes (New Zealand 
white, either sex), a weight of 1.5-2 kg obtained from the 
institutional animal house [16]. Experimental animals were 
acclimatised for 4 d before starting the experimental work. 0.1 ml of 
the optimised formulation of Moxifloxacin hydrochloride was used 
for administration into the cul-de-sac and observed at 1, 24, 48, and 
72 hr. the procedure is repeated for the duration of 7 d. The animals 
were evaluated for the watering of eyes, redness, mucosal discharge 
and swelling [17]. 
RESULTS AND DISCUSSION 
Pre-formulation studies 
Melting point 
The melting point of the sample was found to be 235-239°C, which is 
very close to the theoretical melting point i.e 238-242°C, indicating 
Moxifloxacin with high purity. 
Determination of λmax in distilled water and STF 
The λmax of the Moxifloxacin Hydrochloride was found to be 288 nm 




Fig. 1: Fig. shows the UV scan of mmoxifloxacin hydrochloride in distilled water 
 
Standard calibration curve for Moxifloxacin hydrochloride in 
distilled water and STF 
Standard calibration curve for Moxifloxacin hydrochloride in double 
distilled water (fig. 3) and STF (fig. 4) respectively. Equation of the 
line and R-square value was found to be. 
Conc. = 11.3505 * A, R=0.9980 (for distilled water) 
Conc. = 10.0489 * A, R=0.9995(for STF) 
FTIR analysis 
FTIR scan of the sample drug compared to standard confirmed the 
purity of sample that showed similar FTIR graph as standard 
Moxifloxacin hydrochloride (fig. 5). FTIR analysis compared to 
standard drug shows characteristic peaks in close agreement with 
standard, indicating Moxifloxacin hydrochloride with high purity 
(table 5). 
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Fig. 2: Fig. shows the UV scan of Moxifloxacin hydrochloride in STF 
 
 
Fig. 3: Standard calibration curve for Moxifloxacin hydrochloride in double distilled water, *mean±SD (n=3) 
 
 
Fig. 4: Standard calibration curve for Moxifloxacin hydrochloride in STF, *mean±SD (n=3) 
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Table 5: Shows the characteristic peak of the standard drug compared to the test sample 
Functional group Expected frequency in pure drug (cm-1) Observed frequency in the test sample (cm-1)  
-F 1400-1000 1081 
-C=O 1650-1700 1620 
-NH stretching 3500-3100 3524 
O-H (carboxylic group) 2700-2500 2523 
Aromatic substitution 788 770 
 
 
Fig. 5: Fig. shows FTIR spectrum of sample Moxifloxacin hydrochloride 
 
 
Fig. 6: Fig. shows FTIR spectrum of freshly prepared mixture of drug and excipients mixture 
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Fig. 7: Fig. shows FTIR spectrum of mixture of drug and excipients after completion of 14 d 
 
Drug-excipient compatibility study 
The FTIR graph of the formulation (fig. 7) after compatibility testing 
was compared with freshly prepared formulation (fig. 6) that 
showed no new peaks formation and indicates that there is no 
product degradation with time and compatibility of the ingredients 
of formulation with each other. 
Screening of influential factors 
The performance of in-situ gel was dependent on a number of 
formulation variables and process variables, which can influence 
each other and make it extremely difficult to study individual 
formulation by conventional approaches thus, requiring a greater 
amount of resources [18]. Hence, it is important for the individual or 
organization to implement FbD, to minimize the requirement. 
In our study screening of various formulation and process variables 
significantly influencing, MRT, GT, and viscosity were done using 
Taguchi screening design for seven factors at two levels individually. 
Implementation of pre-optimization study helps in the identification 
of significant factors influencing response for further optimization 
study with maximum efficiency while utilizing minimum resources. 
Principally, screening relies upon the phenomenon of “sparsity 
effect” in which only few of the influential factors significantly affect 
the responses, thus, truly explaining a large proportion of 
experimental variation. The factors responsible for significant 
variation in responses are termed as influential factors, while others 
are termed as non-influential factors. 
Model generation 
The screening predicts considerable approximation of the 
combination of several factors and the lack of interaction. Thus, the 
first order Taguchi design was employed, and interaction terms 
were ignored. Taguchi design had an advantage of requiring the 
minimal number of runs (i.e. 12) for many independent variables 
(i.e. 6). The first order polynomial equation generated for response 
variables (i.e. MRT, GT, and viscosity) has been shown in Equation 0. 
y = β0+β1 χ 1+β 2 χ 2+β 3 χ 3+β 4 χ 4+β 5 χ 5+β 6 χ 6+€. (0) 
where,‘€’ represents the noise or error,  
‘χ’ represent an independent variable,  
‘y’ represents response and  
‘β’ represents the coefficient.  
The first-order mathematical model for each response variable has 
shown statistically significant (p<0.005), those coefficients were 
identified as significant through ANOVA and half normal plots were 
left in simplified equations. Variables having the coefficient with p-
value were characterized as insignificant. The polynomial equations 
of every response variable had high values of r2, indicating excellent 
fit to experimental data. 
Model analysis 
As shown by the fig. 8, the pluronic F-127 (B) concentration, shows a 
significant effect on the studied response MRT, GT, and viscosity. 
Gellan-gum (C) and Carbopol (D) concentration also showed the 
significant effect on response parameter, hence were selected as 
influential factor variables for the formulation of in-situ gel of 
Moxifloxacin hydrochloride. 
Systemic optimization study 
The objective of the pre-optimization study was to identify the 
significant factors influencing the formulation properties. 
Calculation of coefficients 
Independent variables including Pluronic F-127, Carbopol and 
Gellan-gum were evaluated for their final effect on MRT, GT and 
viscosity. Total 13 experiments were conducted, and the response 
data were generated in according to BBD (table 4).  
Final data obtained from the experiments were well modelled by the 
independent variable linear function. Hence the first order 
polynomial equation was used for approximating the function. 
y = β0+β1 χ 1+β 2 χ 2+β 3 χ 3+€ (1) 
‘€’ represents the noise or error,  
‘χ’ represent an independent variable,  
‘y’ represents response and  
‘β’ represents the coefficient.  
The value of responses y1 (MRT), y2 (GT) and y3 (viscosity) varies 
from 2.6 to 3.1 hr, 17 to 36 °C, and 210 to 485 m. Pa. S (table 6). The 
ratio of maximum to minimum response for response y1, y2, and y3 
was 1.19, 2.11, and 2.3 respectively. Thus, power transformation 
was not applicable to the obtained values. The model section for 
response analysing was according to the sequence model sum of the 
square, lack of fit test and model summary statistics. The Prob>F 
value of p<0.0001, low standard deviation, high R-square value and 
lower predicted residual error sum of square (PRESS) value 
recommend selecting the linear model for analysing the responses. 
Analysis of variance (ANOVA) was applicable to determine the effect 
of variables and their interaction. The regression model was used to 
develop contour plots of independent factors. The ANOVA table 
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than 0.05). It also determines the powerful factors that affect the 
response y1, y2 and y3 of the formulation. For MRT, the 
concentration of Gellan-gum played a significant role, followed by 
other 2 factors. 
Moreover, for GT, the concentration of polymer Pluronic was 
determined as the significant model term, whereas for viscosity 
concentration of Gellan-gum was found to be significant compared 





Fig. 8: Pareto and a half-normal chart showing the effect of (B) Pluronic F-127, (C) Gellan-gum, and (D) Carbopol on the response 
variables studied for in-situ gel 
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Table 6: Composition of various factors used in in-situ gel for ocular preparation of Moxifloxacin hydrochloride and responses 
Run Factors Responses 
Pluronic F-127 Gellan-gum Carbopol MRT (h) GT ( °C) Viscosity (mPa. S) 
1 10 0.3 0.5 2.9±0.05 34±0.12 295±0.34 
2 15 0.1 0.5 2.8±0.06 27±0.14±0.14 250±0.14 
3 20 0.5 0.3 3.1±0.05 17±0.16 485±0.24 
4 10 0.3 0.1 2.7±0.08 36±0.06 255±0.14 
5 15 0.1 0.1 2.6±0.12 29±0.14 210±0.14 
6 10 0.1 0.3 2.6±0.08 36±0.08 225±0.24 
7 15 0.5 0.5 3.1±0.12 24±0.19 460±0.22 
8 10 0.5 0.3 2.9±0.14 33±0.22 475±0.14 
9 20 0.3 0.1 2.9±0.12.12 20±0.14 265±0.14 
10 20 0.3 0.5 3.1±0.13 18±0.14 307±0.24 
11 20 0.1 0.3 2.8±0.08 20±0.18 235±0.14 
12 15 0.3 0.3 2.9±0.12+0.12 27±0.24 280±0.14 
13 15 0.5 0.1 2.9±0.22 26±0.14 460±0.14 
All readings were taken in triplicate (n=3), (mean±std. deviation) 
 
Table 7: ANOVA response for the surface model of MRT, GT and viscosity 
Source Sum of squares df F-value Prob>F P-value 
y1 y2 y3 y1 y2 y3 y1 y2 y3 y1 y2 y3 
Model 0.34 538.00 1.650E+005 3 3 9 132.60 2098.20 130.63 <0.0001 <0.0001  0.0010 
A 0.080 512.00 220.50 1 1 1 93.60 5990.40 1.57 <0.0001 <0.0001 0.2988 
B 0.18 18.00 1.152E+005 1 1 1 210.60 210.60 820.90 <0.0001 <0.0001 <0.0001 
C 0.080 8.00 34060.50 1 1 1 93.60 93.60 242.71 <0.0001 <0.0001 0.0006 
Residual 7.692E-003 0.77 421.00 9 9 3 - - - - - - 
Cor total 0.35 538.77 1.654E+005 12 12 12 - - - - - - 
 
Optimization of formulation 
Details of ANOVA of response y1, y2 and y3 as described in table 7. 
The eventual mathematical model determined by software design-
expert was demonstrated in equation 2, 3 and 4. 
y1 (MRT) =+2.194+0.020 ∗ A+0.750 ∗ B+0.50∗ C. (2) 
y2 (GT) =+54.442–1.600∗ A–7.500∗ B–5.000∗C. (3) 
y3 (Viscosity) =+234.625–5.400∗ A–371.250∗ B+215.00∗ C. (4) 
The positive sign represents a synergistic effect, whereas a negative 
sign represents an antagonistic effect.  
In case of the y1 positive coefficient of A in the model refers to an 
increase in MRT at higher concentration of Pluronic F-127. Similarly, 
the positive coefficient of B and C indicated the increase in MRT with 
increasing other factors (Pluronic, Carbopol and Gellan-gum 
concentration). For y2, the negative coefficient of A, B, C referred to 
decrease in GT as an increase in the concentration of other factors. 
Whereas for the y3 negative coefficient of A and B referred to 
decrease in viscosity as the concentration of these factors increases, 
and positive coefficient represented the increase in the viscosity 
with an increase in the concentration of factor C. 
Optimization of formulation using a numerical optimization 
method 
Optimization of the formulation was performed to determine the 
levels of factors A, B, C where yield response of y1 was 2.6 to 3.1 hr 
(target 2.85), y2 was 17 to 36 (target 35) and y3 was 210 to 560 m. 
Pa. S (goal: minimize). This model predicted y1, y2 and y3 in the 
required range at A, B, and C values of 11.50 (g), 0.32 (g), 0.3 (g) 
respectively for a batch size of 200 g. Based on these values, three 
different batches of the in-situ gelling preparation were prepared 
and found that the obtained values were the very close agreement to 
the predicted values, which establishes the reliability of the 
optimization process. In fig. 9 the overlay plot has shown the 
optimised formulation as suggested by design expert software for 
desired range response.  
Finally, the optimised concentration of variable factors was found to 
be, pluronic (5.75% w/v), gellan-gum (0.16% w/v), carbopol (0.15% 
w/v) and the final formulation is presented in table 8. 
 
Table 8: Final optimised formulation details 
S. No. Ingredients  Quantity (g) 
1 Moxifloxacin hydrochloride 0.5 
2 Pluronic F-127 5.75 
3 Gellan-gum 0.16 
4 Carbopol 0.15 
5 Benzalkonium chloride 0.006 
6 Distilled water Quantity sufficient for 100 g 
 
Evaluation of systematically optimised formulation 
Physical appearance 
The prepared in-situ gel formulation was pale yellow, with no odour, 
homogeneous, consistent and non-gritty in nature. 
Drug content 
Drug content of the formulation was determined by UV method. Each 
100 g of in-situ gel contains 0.497 g of moxifloxacin hydrochloride 
which indicates the percentage of drug content to be 98.29+0.43. 
(n=3) that complies with the official standard of 95-105%. 
Drug release (in vitro release study) 
In vitro release studies were done to evaluate the amount of drug 
released in STF. Periodically samples were withdrawn from the 
modified dissolution apparatus and analysed by UV-
spectrophotometer at 287 nm. The percentage cumulative release of 
drug was shown in fig. 10. 
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Fig. 9: 3-D surface plot for optimised parameter of in-situ gelling preparation. A. represent the 3-D graph of desirability, B. represents the 3-D 
surface plot of GT. C. represents the MRT, and D represents the viscosity 3-D surface plots. (To check concentrations of polymers on axis) 
 
 
Fig. 10: In vitro release profile of Moxifloxacin hydrochloride from optimised formulation of in-situ gelling system, *mean±SD (n=3) 
 
Release kinetics 
The results of in vitro release profile obtained for all the 
formulations were plotted in kinetic models as follows:  
a) Cumulative percent drug released versus time (zero order kinetic 
model). 
b) Log cumulative percent drug remaining to be absorbed versus 
time (first-order model).  
c) Amount of drug release or cumulative amount of drug release 
versus square root of time (Higuchi model). 
d) Log Mt/M∞ versus log time (Korsmeyer’s pepas model). 
The kinetics of drug release can be estimated by comparing R2 
values from graphs. R2 value is higher for in-situ gel optimised 
batch (R2 value: 0.9941) for higuchi model (table 9). Hence in-
situ gel follows sustain release kinetics. The mechanism of drug 
release of the final formulation was determined by comparing 
the slope values of log CR v/s log time (pepas plot) with the 
standard values of Korsmeyer’s pepas model. Slope of pepas plot 
was found to be 1.3567 for an in-situ gel which was greater than 
1. This indicates that the mechanism of drug release to be super 
case-II transport [19]. 
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Table 9: Release kinetics for optimised formulation of in-situ gel 
Formulation  Zero order First order Higuchi model Korsmeyer’s and pepas model Best fit model 
Slope R2 Slope R2 Slope R2 Slope R2 
Test 10.744 0.9361 0.1668 0.5456 33.752 0.9941 1.3567 0.5704 Higuchi Model 
 
Antimicrobial activity 
Antibacterial activity of optimised formulation was compared 
against the marketed formulation. Table 10 showed the ZOI 
obtained by the prepared formulation of Moxifloxacin 
hydrochloride as compared to the marketed formulation. The 
higher ZOI obtained by synthesized formulation indicate the 
potency of formulation that can relate the higher viscosity of 
formulation which results in slow and prolong the release of drug 
from the formulation [14]. 
 
Table 10: Anti-bacterial potency of synthesized and marketed formulation 
Formulation Zone of inhibition (diameter in mm) 
Pseudomonas aueroginosa Staphylococcus aureus 
Selected formulation  31.4±0.8 31.1±0.7 
Marketed formulation 31.3±1.4 30.2±1.2 
*All values were represented as mean±SD (n=3).  
 
Sterility testing 
No turbidity was observed in either of the media inoculated with the 
sterile preparations, indicating no microbial growth in the samples 
incubated for more than 14 d. This confirms that the prepared 
formulation passed the sterility test. 
Accelerated stability study  
Accelerated stability studies of the optimised formulation showed no 
significant changes in the visual appearance, pH, gelling capacity, 
drug content, and in vitro drug release which confirm the stability of 
the optimised formulation for a long duration. 
Isotonicity evaluation 
In isotonicity evaluation, the measure of tonicity of the formulation was 
done by observing the structural alteration in blood cells. It is the 
amount of osmotic pressure exerted by two different solutions separated 
by the semi-permeable membrane. It is extremely important for the 
ophthalmic formulation to be isotonic because non-isotonic formulations 
can cause irritation in the eyes and may cause excessive tearing. 
The isotonicity of the formulation was evaluated by comparing against 
0.9% NaCl as shown in fig. 11 and 12 respectively. The formulation didn’t 
rupture the red blood cells and was found to be isotonic. 
Ocular irritancy test 
An equal amount of optimised formulation and standard marketed 
formulation has shown no ocular irritancy on rabbit eyes (New 
Zealand White) after exposure of consecutive 14 d duration. No 
watering from eyes, mucosal discharge and swelling were found 
during the specified period. This implies the biocompatibility and 
non-irritancy of optimised formulation in the biological system [20]. 
 
 
Fig. 11: Blood cells exposed with 0.9% NaCl 
 
Fig. 12: Blood cells exposed with the formulation 
 
CONCLUSION 
Considering the prescribing trends in ocular infections and need for 
advanced drug delivery which could decrease the precorneal 
elimination of instilled drug and loss due to nasolacrimal drainage. 
Moxifloxacin hydrochloride in-situ gelling formulations were 
developed and analysed in the present study. As desired the 
prepared formulation was liquid at non-physiological conditions and 
was transformed to gel form under physiological conditions (pH 7.4 
and 37 °C). Preformulation studies established the authenticity of 
the drug sample and its compatibility with the polymers used in the 
formulation. Taguchi method was used for pre-optimization to 
determine critical influential factors for the formulation. 
Optimization of the in-situ gelling formulation using influential 
factors Pluronic F-127, Carbopol and Gellan-gum was further done 
by BBD. A complex process since it involves many variables, which 
affect the characteristics of the final formulation. The concentration 
of Pluronic F-127, Carbopol, and Gellan-gum, play a critical role to 
influence MRT, GT and viscosity of the final formulation. GT was 
more concerned with Pluronic concentration and the MRT and 
viscosity of the product were more dependable on the concentration 
of Carbopol and Gellan-gum. The supportive study including 
compatibility, stability study, antimicrobial assessment, isotonicity 
and ocular irritancy test confirmed the long durability with 
significant potency of optimised formulation. The finalized 
formulation is a possible substitution to traditional eye drop by its 
proficiency to increased and extended antibacterial potency. 
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